Publication | Closed Access

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the???Introduction of New Disease-Modifying Agents

Relapsing-remitting Multiple SclerosisHealth PolicyHealth EconomicsMedicineNeurological DisorderClinical TrialsOutcomes ResearchPharmacoeconomicsNeurologyCost EffectivenessMultiple SclerosisNeuroimmunologyNew Disease-modifying AgentsNeurological SurgeryHealth Sciences